ADIA Nutrition Inc. Requests SIC Code Update to 2836 (Biological Products) with SEC and OTC MarketsNovember 17, 2025 8:00 AM EST | Source: Adia Nutrition Inc.Winter Park, Florida--(Newsfile Corp. - November 17, 2025) - ADIA Nutrition, Inc. (OTCQB: ADIA), a leader in regenerative medicine, today announced it has filed with the SEC to update its Standard Industrial Classification (SIC) code from 2834 (Pharmaceutical Preparations) to 2836 (Biological Products, Except Diagnostic) and with OTC Mark ...

Core Insights - Kelyniam Global, Inc. has secured an exclusive U.S. license from Evonik Industries AG to market VESTAKEEP® Fusion, a bi-calcium phosphate-infused PEEK material for cranial, craniofacial, and maxillofacial implants, with a two-year exclusivity period and an option for renewal [1][2][3] Company Developments - The incorporation of VESTAKEEP® Fusion enhances Kelyniam's regenerative product lineup by leveraging its osteoconductive properties, which promote human bone growth and integration [2][4] - This strategic move is expected to add significant value for shareholders by expanding Kelyniam's regenerative medicine portfolio, positioning the company to meet the increasing demand for innovative cranial reconstruction solutions [3][4] Product and Market Positioning - Kelyniam's partnership with Modern Plastics ensures reliable access to PEEK materials, supporting the company's growth in advanced neurosurgical solutions [2][3] - The introduction of VESTAKEEP® Fusion reflects Kelyniam's commitment to delivering regenerative technologies that improve patient outcomes and advance the standard of care in cranial and craniofacial solutions [4]

Adia Med Files Provisional Patent for Breakthrough Regenerative Medical ProtocolNovember 12, 2025 9:15 AM EST | Source: Adia Nutrition Inc.Winter Park, Florida--(Newsfile Corp. - November 12, 2025) - ADIA Nutrition, Inc. (OTCQB: ADIA), a leader in advanced regenerative health solutions, today announced the filing of a provisional patent application with the United States Patent and Trademark Office (USPTO) for a novel medical protocol designed to enhance regenerative outcomes.This Patent Pendi ...

Humacyte (NasdaqGS:HUMA) Q3 2025 Earnings Call November 12, 2025 08:00 AM ET Speaker2Good morning ladies and gentlemen and welcome to the Humacyte third quarter results conference call. Currently all participants are in a listen only mode. Later we will conduct a question and answer session and instructions will follow at that time. As a reminder, this conference call is being recorded. I'll now turn the call over to Tom Johnson with LifeSci Advisors. Please go ahead.Speaker4Thank you, operator. Before we p ...

Core Insights - Healios K.K. is set to present at the Jefferies Global Healthcare Conference in London on November 17, 2025, at 4:00 PM GMT [1] - The company is a leading clinical stage biotechnology firm in Japan, focusing on regenerative medicine through stem cell technology [3] Company Overview - Healios K.K. specializes in developing therapies for diseases lacking effective treatment options, utilizing both somatic stem cells and induced pluripotent stem (iPS) cells [3] - The company is advancing MultiStem® (HLCM051), a proprietary cell product derived from adult bone marrow, which has shown anti-inflammatory and immunomodulatory properties [3] - MultiStem has been tested in late-stage clinical trials with hundreds of patients, demonstrating safety and suggested efficacy across multiple indications [3] - Healios is also developing HLCN061, a next-generation NK cell treatment for solid tumors, which has shown robust anti-tumor efficacy in animal models and is preparing for initial human testing [3] - The company has established a gene-edited "universal donor" iPS cell line aimed at developing treatments in various fields, including immuno-oncology and ophthalmology [3] - Healios was founded in 2011 and has been publicly listed on the Tokyo Stock Exchange since 2015 under the code 4593 [3]

Investment & Industry Focus - YZi Labs (formerly Binance Labs) made its first biotech investment in 2025, indicating a strategic expansion into regenerative medicine [1] - The investment targets Renewal Bio, a regenerative medicine firm addressing the global organ shortage [1] Technology & Innovation - Renewal Bio utilizes its Stembroid™ platform to create DNA-identical human cells and tissues [1] - The technology aims to provide patient-specific cells and tissues, potentially revolutionizing organ replacement therapies [1]

Investment Focus - YZILABS makes first biotech investment [1] - Investment targets Renewal Bio [1] - Focus on regenerative medicine to address global organ shortages [1]

Main Argument - The body possesses innate self-healing capabilities that can be harnessed to treat various conditions [3][4][5] - Regenerative medicine, particularly stem cell therapies, offers a promising approach to enhance self-healing and improve patient outcomes [9][22] - Misinformation and the corporatization of healthcare hinder the broader adoption of regenerative therapies [16][17][31] Clinical Evidence & Statistics - A Mayo Clinic stem cell trial showed that 70% of patients with spinal cord injuries had measurable functional improvements [13] - A Yale stem cell study showed benefit in 12 out of 13 patients, with over half showing measurable motor improvements [13] - A 2023 meta-analysis of 68 patients showed that stem cell injections for disc disease resulted in a significant improvement in pain scale and a 12-point reduction on a standard disability index [26] - Globally, 1 billion people suffer from back and neck pain, the leading cause of disability worldwide [14] - In the US alone, 25 million people suffer from chronic daily pain, with spine conditions being a primary cause [14] - There are 18,000 new spinal cord injuries each year in the US [14] Call to Action - Challenge the status quo and break down silos in healthcare to provide patients with access to regenerative therapies [32] - Patients should become proactive in their health and inquire about available therapies [32] - Share the message about the body's self-healing power and consider donating to research [33][34]

Core Insights - Visionary Holdings Inc. has officially launched its medical-grade stem cell anti-aging product line, targeting the Chinese mainland and broader Asian markets [1][2] - This launch follows the company's entry into the stem cell and medical aesthetics sector and a strategic partnership with Jiangsu Yike Regenerative Medicine Co., Ltd. [2][3] Product Lines and Value Model - The anti-aging product portfolio includes three major categories: Life Rejuvenation Program, Precision Repair Package, and Premium Personalized Program [6] - The Life Rejuvenation Program combines mesenchymal stem cells, NK cell therapy, and AI-based diagnostics, aimed at high-net-worth individuals [6] - The Precision Repair Package integrates targeted stem cell therapy and blood purification for clients with specific conditions [6] - The Premium Personalized Program offers full-genome sequencing and customized health management for ultra-high-net-worth clients [6] Commercialization Strategy - The new products will be operated through the Asia-Pacific headquarters in Hong Kong, initially launching in Hong Kong, Singapore, and the Chinese mainland [4] - The company plans to establish a joint venture for localized manufacturing and validation of stem cell products [7] - A cross-border sales and distribution network will be built, covering mainland China, Hong Kong, Southeast Asia, and expanding into Canada, the United States, and Mexico [7] Management Perspective - The CEO of Visionary Holdings emphasized that the launch marks a significant milestone in converting technological assets into commercial value [4] - The company anticipates that this product line will drive profitability in upcoming fiscal years and enhance its visibility in global capital markets [5]

CANTON, Conn., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Kelyniam Global, Inc. (OTC: KLYG), a leading manufacturer of custom cranial and cranio-maxillofacial implants, today announced the renewal of its licensing agreement with Finceramica Faenza S.p.A., an innovative Italian biomaterials company. The three-year extension strengthens the longstanding partnership, granting Kelyniam expanded access to Finceramica's advanced product portfolio, including SINTlife, a next-generation fully resorbable synthetic graft made ...